Abstract

Epithelial ovarian cancer (EOC) is a deadly disease with limited diagnostic biomarkers and therapeutic targets. Here we conduct a comprehensive proteomic profiling of ovarian tissue and plasma samples from 813 patients with different histotypes and therapeutic regimens, covering the expression of 10,715 proteins. We identify eight proteins associated with tumor malignancy in the tissue specimens, which are further validated as potential circulating biomarkers in plasma. Targeted proteomics assays are developed for 12 tissue proteins and 7 blood proteins, and machine learning models are constructed to predict one-year recurrence, which are validated in an independent cohort. These findings contribute to the understanding of EOC pathogenesis and provide potential biomarkers for early detection and monitoring of the disease. Additionally, by integrating mutation analysis with proteomic data, we identify multiple proteins related to DNA damage in recurrent resistant tumors, shedding light on the molecular mechanisms underlying treatment resistance. This study provides a multi-histotype proteomic landscape of EOC, advancing our knowledge for improved diagnosis and treatment strategies.

It remains essential to find clinically relevant biomarkers in epithelial ovarian cancer (EOC). Here, the authors perform a comprehensive proteomic profiling of tissue and plasma samples from EOC and control patients; they find potential biomarkers for EOC early detection and develop methods for tumour recurrence prediction.

Details

Title
Proteomic landscape of epithelial ovarian cancer
Author
Qian, Liujia 1 ; Zhu, Jianqing 2   VIAFID ORCID Logo  ; Xue, Zhangzhi 1 ; Zhou, Yan 1 ; Xiang, Nan 1 ; Xu, Hong 3 ; Sun, Rui 1 ; Gong, Wangang 2 ; Cai, Xue 1 ; Sun, Lu 2 ; Ge, Weigang 4 ; Liu, Yufeng 3 ; Su, Ying 2 ; Lin, Wangmin 4 ; Zhan, Yuecheng 4 ; Wang, Junjian 2 ; Song, Shuang 3   VIAFID ORCID Logo  ; Yi, Xiao 1 ; Ni, Maowei 2 ; Zhu, Yi 1   VIAFID ORCID Logo  ; Hua, Yuejin 3   VIAFID ORCID Logo  ; Zheng, Zhiguo 2   VIAFID ORCID Logo  ; Guo, Tiannan 1   VIAFID ORCID Logo 

 Westlake University, School of Medicine, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315); Westlake Laboratory of Life Sciences and Biomedicine, Westlake Center for Intelligent Proteomics, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315); Westlake University, Research Center for Industries of the Future, School of Life Sciences, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315); Westlake University, Affiliated Hangzhou First People’s Hospital, School of Medicine, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315) 
 Zhejiang Cancer Hospital, Hangzhou, China (GRID:grid.417397.f) (ISNI:0000 0004 1808 0985); Chinese Academy of Sciences, Hangzhou Institute of Medicine (HIM), Hangzhou, China (GRID:grid.9227.e) (ISNI:0000 0001 1957 3309) 
 Zhejiang University, MOE Key Laboratory of Biosystems Homeostasis and Protection, Institute of Biophysics, College of Life Science, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Ltd., Westlake Omics (Hangzhou) Biotechnology Co., Hangzhou, China (GRID:grid.9227.e) 
Pages
6462
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3086465136
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.